pz-128
Small moleculeexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01806077)
Timeline
Indications
Mechanism of action
protease-activated receptor antagonist
- Proteinase-activated receptor 1INHIBITOR
Proteinase-activated receptor 1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCCCCCCCCCCCCCCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(N)=O- Mol. weight
- 1086.48 g/mol
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297323 ↗
Also known as
- pz-128
- pz-128
- pz-128
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02561000 | Phase 2 | Apr 1, 2016 | Inova Health System, National Heart, Lung, and Blood Institute (NHLBI), RTI International, Tufts University, University of Massachusetts |
| NCT01806077 | Phase 1 | Apr 1, 2013 | LifeBridge Health, National Heart, Lung, and Blood Institute (NHLBI), Tufts University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 2 | 0 | 2 | 2013 |
| Tufts University | Academic/Hospital | 2 | 2 | 2 | 2013 |
| Inova Health System | Academic/Hospital | 1 | 0 | 1 | 2016 |
| LifeBridge Health | Academic/Hospital | 1 | 0 | 1 | 2013 |
| RTI International | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Massachusetts | Academic/Hospital | 1 | 0 | 1 | 2016 |
6 organizations
Page 1 / 1